Accueil・Liste d'Actions・Viatris Inc

Viatris Inc

Fermé

SecteurSoins de santé

16.23 1.18

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

15.85

Max

16.26

Chiffres clés
By Trading Economics
Revenu	-295M -119M
Ventes	240M 3.8B
BPA	0.69
Rendement du dividende	2.92
Marge bénéficiaire	-3.162
Employés	30,000
EBITDA	9.4M 653M

Recommandations
By TipRanks
Recommandations	Neutre
Prévisions sur 12 Mois	+13.28% upside

Dividendes
By Acuity
Rendement du dividende Moyenne du Secteur	2.92% 2.22%
Prochains Résultats	5 nov. 2026
Date du Prochain Dividende	16 sept. 2026
Date du Prochain Détachement de Dividende	21 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-1.8B 19B
Ouverture précédente	15.05
Clôture précédente	16.23

Sentiment de l'Actualité

By Acuity

50%

163 / 340 Classement par Healthcare

Viatris Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 août 2026, 20:06 UTC

Viatris Inc shares are higher today, despite earlier session pullbacks. Broader market sentiment is mixed following a decline in U.S. retail sales.

13 août 2026, 20:06 UTC

Viatris Inc shares are lower today, reflecting broader market trends amid rising U.S. jobless claims that exceeded expectations. The stock remains near its one-month range low.

12 août 2026, 23:06 UTC

Viatris Inc. shares moved higher in after-market trading, recovering from earlier losses. The stock remains below its 20-day moving average.

11 août 2026, 23:41 UTC

Viatris Inc. shares rose in after-market trading, despite earlier fluctuations and broader market concerns about inflationary pressures and oil prices.

10 août 2026, 19:42 UTC

Pharmaceuticals sector strength is lifting Viatris Inc during Monday's session, with increased trading volume contributing to the upward movement.

7 août 2026, 22:01 UTC

Viatris Inc. shares are higher in after-market trading, supported by a broader equity rally following weaker employment data and reduced interest rate hike concerns.

6 août 2026, 23:01 UTC

Viatris Inc shares are higher in after-market hours, recovering from earlier lows. The stock is trading above Thursday's close despite recent declines.

5 août 2026, 23:11 UTC

Viatris Inc. shares are trading higher in after-market hours, recovering significantly above the 20-day moving average amid broader market optimism despite no specific news.

4 août 2026, 23:06 UTC

Viatris Inc shares are higher in after-market trading, reflecting positive momentum and positioning above the 20-day moving average. No specific news was identified.

3 août 2026, 20:06 UTC

Viatris Inc shares are higher today, reflecting broader market gains led by major stocks. The S&P 500 and Nasdaq 100 have also risen.

31 juil. 2026, 21:02 UTC

Viatris Inc shares are lower in after-market hours, continuing a four-session decline amid rising inflation concerns and higher crude oil prices.

30 juil. 2026, 18:56 UTC

Event

Viatris shares are trading lower despite FDA approval of the Gwyn Lo contraceptive patch. Broader economic data may be impacting the stock's performance.

29 juil. 2026, 22:03 UTC

Event

Viatris Inc. shares are lower in after-market hours despite FDA approval of the Gwyn Lo contraceptive patch, amid broader market caution over geopolitical tensions.

28 juil. 2026, 19:36 UTC

Social Media

Viatris shares are higher today, supported by strong sector gains and a significant rise in January 2027 $10 call options activity.

27 juil. 2026, 19:11 UTC

Viatris Inc shares are higher today, breaking a trend of daily gains. No specific news was identified to explain this movement.

23 juil. 2026, 20:06 UTC

Viatris Inc's shares are higher during Thursday's session, continuing an upward trend since Wednesday's close. No specific news was identified to explain the movement.

22 juil. 2026, 23:16 UTC

Viatris Inc shares are higher in after-market hours, recovering from an earlier dip and reflecting strength amid rising crude oil prices.

21 juil. 2026, 18:46 UTC

Viatris Inc shares are higher today, rebounding after an earlier dip amid a broader recovery in U.S. markets and renewed investor optimism.

20 juil. 2026, 19:21 UTC

News

Viatris Inc shares are lower amid negative sentiment in the Pharmaceuticals sector. Analysts cite a price target of $17.81, reflecting concerns over sales declines.

Comparaison

Variation de prix

Viatris Inc prévision

Objectif de Prix

By TipRanks

13.28% hausse

Prévisions sur 12 Mois

Moyen 18.17 USD 13.28%

Haut 23 USD

Bas 12 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

6 ratings

Achat

Maintien

Vente

Basé sur 6 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

163 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Viatris Inc

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.